Join out host, Larry Zeifman and this week's guests, Dr. Joseph Tucker, CEO of MagicMed Industries and Kelsey Ramsden, President & CEO of MINDCURE as they discuss the rapid growth of the psychedelic industry, predict future changes within the industry and changes required for psychedelics to become mainstream.
Zeifmans is a full-service tax, accounting and consulting firm based in Toronto, Canada, ranked as one of Canada’s top 20 firms by revenue. Beyond the traditional offering, our services include business advisory, valuation, corporate finance, transaction services, corporate turnaround and insolvency, and estate and succession planning, supporting our 9,000+ clients through every step of the business life cycle. For more on our services relating directly to the cannabis and psychedelics industry, visit zeifmans.ca.
About MagicMed Industries
MagicMed Industries intends to partner with pharmaceutical and other companies to develop psychedelic-derived medicinal and licit consumer goods products. MagicMed's molecular derivatives library, the PsybraryTM is anticipated to be an essential building block from which industry can develop new patented products. The initial focus of the PsybraryTM is on psilocybin, which is expected to be opportunistically expanded to other psychedelics like MDMA, ketamine, Ibogaine, Mescaline, and Ayahuasca.
About MINDCURE
MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care. MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.